,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Dr. Emil D. Kakkis M.D., Ph.D.', 'age': 62, 'title': 'Founder, Pres, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1366354, 'exercisedValue': 0, 'unexercisedValue': 1888758}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
1,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. John Richard Pinion II', 'age': 56, 'title': 'Chief Quality Operations Officer & Exec. VP of Translational Sciences', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 806193, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
2,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Erik  Harris', 'age': 51, 'title': 'Exec. VP & Chief Commercial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 848237, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
3,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Theodore A. Huizenga', 'age': 51, 'title': 'Sr. VP, Corp. Controller & Principal Accounting Officer', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
4,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Dennis Karl Huang', 'age': 57, 'title': 'Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP', 'yearBorn': 1965, 'fiscalYear': 2015, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
5,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Ms. Danielle  Keatley', 'title': 'Sr. Director of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
6,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Ms. Karah Herdman Parschauer J.D.', 'age': 44, 'title': 'Chief Legal Officer & Exec. VP', 'yearBorn': 1978, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
7,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Ernie W. Meyer', 'age': 58, 'title': 'Chief HR Officer & Exec. VP', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
8,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Thomas R. Kassberg', 'age': 62, 'title': 'Chief Bus. Officer & Exec. VP', 'yearBorn': 1960, 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
9,60 Leveroni Court,Novato,CA,94949,United States,415 483 8800,https://www.ultragenyx.com,Biotechnology,Healthcare,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",1311,"{'maxAge': 1, 'name': 'Mr. Vimal  Srivastava', 'age': 57, 'title': 'Sr. VP of Bus. Devel. & Alliance Management', 'yearBorn': 1965, 'exercisedValue': 0, 'unexercisedValue': 0}",2,1,5,7,4,1693526400,1672444800,86400,2,39.26,39.2,37.5,39.34,39.26,39.2,37.5,39.34,0.0,0.866874,-5.7004538,855275,855275,563919,703280,703280,37.84,37.85,1400,800,2693690368,33.36,54.98,6.6864843,39.8751,43.196575,0.0,0.0,USD,2167120128,-1.78907,62640918,71488600,3448154,3552959,1690761600,1693440000,0.0482,0.04665,0.98579,6.03,0.0505,1.806,20.863787,1672444800,1703980800,1688083200,-720739008,-10.25,-6.61,0.05,1:3,1389916800,5.379,-3.321,NMS,EQUITY,RARE,RARE,Ultragenyx Pharmaceutical Inc.,Ultragenyx Pharmaceutical Inc.,1391178600,America/New_York,EDT,-14400000,37.68,140.0,47.0,89.85,87.0,1.7,buy,20,551980992,7.722,-652508032,25729000,2.557,2.873,402856000,19.94,5.725,-0.31951,-1.78599,-370780000,-391286240,-458715008,0.212,-0.92345,-1.6197,-1.6699699,USD,
